Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?

dc.contributor.authorImamoglu, Goksen Inanc
dc.contributor.authorEren, Tulay
dc.contributor.authorArzu, Oguz
dc.contributor.authorYildirim, Nuriye
dc.contributor.authorKaracin, Cengiz
dc.contributor.authorBaylan, Burhan
dc.contributor.pubmedID31632870en_US
dc.date.accessioned2020-12-16T07:48:55Z
dc.date.available2020-12-16T07:48:55Z
dc.date.issued2019
dc.description.abstractIntroduction: Tamoxifen treatment has been shown to reduce the recurrence and mortality rates in hormone receptor-positive breast cancers independent from chemotherapy. This benefit increases with the prolongation of the use of tamoxifen but with increasing side effects. In this study, we aim to evaluate the presence of urogenital symptoms in breast cancer patients on tamoxifen and compare them with those who are not on any hormonotherapy. Materials and methods: This study was performed on patients diagnosed as early-stage breast cancer. The study group consisted of hormone receptor-positive patients given tamoxifen as adjuvant hormonal therapy. The control group consisted of breast cancer patients who had no hormonotherapy. Patients with a complaint of urinary incontinence with onset after tamoxifen usage were evaluated with Urogenital Distress Inventory Short Form (UDI-6), Incontinence Impact Questionnaire Short Form (IIQ-7) and Incontinence Quality of Life Questionnaire (IQOL). Results: A total of 137 early-stage breast cancer patients were included in this study; 74 estrogen receptor-positive patients on tamoxifen therapy (study group) and 63 hormone receptor-negative patients with no hormonotherapy (control group). The median age was 44 (30-65) years for tamoxifen users and 49 (27-64) years for the control group. The stages of the patients were similar for both groups. 78.4% of the women in the tamoxifen group and 49.2% in the control group were in the premenopausal period. The groups were similar in regard to body mass index and parity. The complaint of urinary incontinence was more frequent in the study group compared to controls (39 (52.7%) vs. 5 (7.9%)). Women with the complaint of urinary incontinence were evaluated with self-reported UDI-6, IIQ-7 and I-QOL forms and the scores were similar for both study and control groups. A statistically significant relation was observed between cigarette smoking and the presence of urinary incontinence. The percentages of smokers were 50% of those with incontinence and 24.7% of those without incontinence. Conclusion: Urinary incontinence is positively correlated with tamoxifen usage in early-stage breast cancer patients.en_US
dc.identifier.eissn2168-8184en_US
dc.identifier.issue8en_US
dc.identifier.urihttps://assets.cureus.com/uploads/original_article/pdf/22217/1571243062-20191016-7315-pocfzg.pdf
dc.identifier.urihttp://hdl.handle.net/11727/5075
dc.identifier.volume11en_US
dc.identifier.wos000484753600004en_US
dc.language.isoengen_US
dc.relation.isversionof10.7759/cureus.5417en_US
dc.relation.journalCUREUSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbreast canceren_US
dc.subjecttamoxifenen_US
dc.subjecturinary incontinenceen_US
dc.titleIs Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?en_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1571243062-20191016-7315-pocfzg.pdf
Size:
108.88 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: